2024-04-012025-03-312025-03-31false14694064EMI MEDICAL AESTHETICS LTD2025-12-1696020falseiso4217:GBPxbrli:pure146940642024-03-31146940642025-03-31146940642024-04-012025-03-31146940642023-02-27146940642024-03-31146940642023-02-282024-03-3114694064bus:SmallEntities2024-04-012025-03-3114694064bus:AuditExempt-NoAccountantsReport2024-04-012025-03-3114694064bus:FullAccounts2024-04-012025-03-3114694064bus:PrivateLimitedCompanyLtd2024-04-012025-03-3114694064core:WithinOneYear2025-03-3114694064core:AfterOneYear2025-03-3114694064core:WithinOneYear2024-03-3114694064core:AfterOneYear2024-03-3114694064core:ShareCapital2025-03-3114694064core:SharePremium2025-03-3114694064core:RevaluationReserve2025-03-3114694064core:OtherReservesSubtotal2025-03-3114694064core:RetainedEarningsAccumulatedLosses2025-03-3114694064core:ShareCapital2024-03-3114694064core:SharePremium2024-03-3114694064core:RevaluationReserve2024-03-3114694064core:OtherReservesSubtotal2024-03-3114694064core:RetainedEarningsAccumulatedLosses2024-03-3114694064core:LandBuildings2025-03-3114694064core:PlantMachinery2025-03-3114694064core:Vehicles2025-03-3114694064core:FurnitureFittings2025-03-3114694064core:OfficeEquipment2025-03-3114694064core:NetGoodwill2025-03-3114694064core:IntangibleAssetsOtherThanGoodwill2025-03-3114694064core:ListedExchangeTraded2025-03-3114694064core:UnlistedNon-exchangeTraded2025-03-3114694064core:LandBuildings2024-03-3114694064core:PlantMachinery2024-03-3114694064core:Vehicles2024-03-3114694064core:FurnitureFittings2024-03-3114694064core:OfficeEquipment2024-03-3114694064core:NetGoodwill2024-03-3114694064core:IntangibleAssetsOtherThanGoodwill2024-03-3114694064core:ListedExchangeTraded2024-03-3114694064core:UnlistedNon-exchangeTraded2024-03-3114694064core:LandBuildings2024-04-012025-03-3114694064core:PlantMachinery2024-04-012025-03-3114694064core:Vehicles2024-04-012025-03-3114694064core:FurnitureFittings2024-04-012025-03-3114694064core:OfficeEquipment2024-04-012025-03-3114694064core:NetGoodwill2024-04-012025-03-3114694064core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3114694064core:ListedExchangeTraded2024-04-012025-03-3114694064core:UnlistedNon-exchangeTraded2024-04-012025-03-3114694064core:MoreThanFiveYears2024-04-012025-03-3114694064core:Non-currentFinancialInstruments2025-03-3114694064core:Non-currentFinancialInstruments2024-03-3114694064dpl:CostSales2024-04-012025-03-3114694064dpl:DistributionCosts2024-04-012025-03-3114694064core:LandBuildings2024-04-012025-03-3114694064core:PlantMachinery2024-04-012025-03-3114694064core:Vehicles2024-04-012025-03-3114694064core:FurnitureFittings2024-04-012025-03-3114694064core:OfficeEquipment2024-04-012025-03-3114694064dpl:AdministrativeExpenses2024-04-012025-03-3114694064core:NetGoodwill2024-04-012025-03-3114694064core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3114694064dpl:GroupUndertakings2024-04-012025-03-3114694064dpl:ParticipatingInterests2024-04-012025-03-3114694064dpl:GroupUndertakingscore:ListedExchangeTraded2024-04-012025-03-3114694064core:ListedExchangeTraded2024-04-012025-03-3114694064dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-04-012025-03-3114694064core:UnlistedNon-exchangeTraded2024-04-012025-03-3114694064dpl:CostSales2023-02-282024-03-3114694064dpl:DistributionCosts2023-02-282024-03-3114694064core:LandBuildings2023-02-282024-03-3114694064core:PlantMachinery2023-02-282024-03-3114694064core:Vehicles2023-02-282024-03-3114694064core:FurnitureFittings2023-02-282024-03-3114694064core:OfficeEquipment2023-02-282024-03-3114694064dpl:AdministrativeExpenses2023-02-282024-03-3114694064core:NetGoodwill2023-02-282024-03-3114694064core:IntangibleAssetsOtherThanGoodwill2023-02-282024-03-3114694064dpl:GroupUndertakings2023-02-282024-03-3114694064dpl:ParticipatingInterests2023-02-282024-03-3114694064dpl:GroupUndertakingscore:ListedExchangeTraded2023-02-282024-03-3114694064core:ListedExchangeTraded2023-02-282024-03-3114694064dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-02-282024-03-3114694064core:UnlistedNon-exchangeTraded2023-02-282024-03-3114694064core:NetGoodwill2025-03-3114694064core:IntangibleAssetsOtherThanGoodwill2025-03-3114694064core:LandBuildings2025-03-3114694064core:PlantMachinery2025-03-3114694064core:Vehicles2025-03-3114694064core:FurnitureFittings2025-03-3114694064core:OfficeEquipment2025-03-3114694064core:AfterOneYear2025-03-3114694064core:WithinOneYear2025-03-3114694064core:ListedExchangeTraded2025-03-3114694064core:UnlistedNon-exchangeTraded2025-03-3114694064core:ShareCapital2025-03-3114694064core:SharePremium2025-03-3114694064core:RevaluationReserve2025-03-3114694064core:OtherReservesSubtotal2025-03-3114694064core:RetainedEarningsAccumulatedLosses2025-03-3114694064core:NetGoodwill2024-03-3114694064core:IntangibleAssetsOtherThanGoodwill2024-03-3114694064core:LandBuildings2024-03-3114694064core:PlantMachinery2024-03-3114694064core:Vehicles2024-03-3114694064core:FurnitureFittings2024-03-3114694064core:OfficeEquipment2024-03-3114694064core:AfterOneYear2024-03-3114694064core:WithinOneYear2024-03-3114694064core:ListedExchangeTraded2024-03-3114694064core:UnlistedNon-exchangeTraded2024-03-3114694064core:ShareCapital2024-03-3114694064core:SharePremium2024-03-3114694064core:RevaluationReserve2024-03-3114694064core:OtherReservesSubtotal2024-03-3114694064core:RetainedEarningsAccumulatedLosses2024-03-3114694064core:NetGoodwill2023-02-2714694064core:IntangibleAssetsOtherThanGoodwill2023-02-2714694064core:LandBuildings2023-02-2714694064core:PlantMachinery2023-02-2714694064core:Vehicles2023-02-2714694064core:FurnitureFittings2023-02-2714694064core:OfficeEquipment2023-02-2714694064core:AfterOneYear2023-02-2714694064core:WithinOneYear2023-02-2714694064core:ListedExchangeTraded2023-02-2714694064core:UnlistedNon-exchangeTraded2023-02-2714694064core:ShareCapital2023-02-2714694064core:SharePremium2023-02-2714694064core:RevaluationReserve2023-02-2714694064core:OtherReservesSubtotal2023-02-2714694064core:RetainedEarningsAccumulatedLosses2023-02-2714694064core:AfterOneYear2024-04-012025-03-3114694064core:WithinOneYear2024-04-012025-03-3114694064core:Non-currentFinancialInstrumentscore:CostValuation2024-04-012025-03-3114694064core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-04-012025-03-3114694064core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-04-012025-03-3114694064core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-04-012025-03-3114694064core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-04-012025-03-3114694064core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-04-012025-03-3114694064core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3114694064core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3114694064core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-04-012025-03-3114694064core:Non-currentFinancialInstrumentscore:CostValuation2025-03-3114694064core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-3114694064core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-3114694064core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-3114694064core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-3114694064core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-3114694064core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-3114694064core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-3114694064core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-3114694064core:Non-currentFinancialInstrumentscore:CostValuation2024-03-3114694064core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-3114694064core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-3114694064core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-3114694064core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-3114694064core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-3114694064core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-3114694064core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-3114694064core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-3114694064bus:Director12024-04-012025-03-31

EMI MEDICAL AESTHETICS LTD

Registered Number
14694064
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2025

EMI MEDICAL AESTHETICS LTD
Company Information
for the year from 1 April 2024 to 31 March 2025

Director

Dr E Ismaili

Registered Address

Flat 151 Park West Edgware Road
London
W2 2QP

Registered Number

14694064 (England and Wales)
EMI MEDICAL AESTHETICS LTD
Balance Sheet as at
31 March 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets32,7972,797
2,7972,797
Current assets
Debtors4,5531,010
Cash at bank and on hand48228
4,6011,238
Creditors amounts falling due within one year4(7,085)(3,888)
Net current assets (liabilities)(2,484)(2,650)
Total assets less current liabilities313147
Net assets313147
Capital and reserves
Called up share capital11
Profit and loss account312146
Shareholders' funds313147
The financial statements were approved and authorised for issue by the Director on 16 December 2025, and are signed on its behalf by:
Dr E Ismaili
Director
Registered Company No. 14694064
EMI MEDICAL AESTHETICS LTD
Notes to the Financial Statements
for the year ended 31 March 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:
2.Average number of employees

20252024
Average number of employees during the year11
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
At 01 April 242,7972,797
At 31 March 252,7972,797
Net book value
At 31 March 252,7972,797
At 31 March 242,7972,797
4.Creditors: amounts due within one year

2025

2024

££
Taxation and social security5,7652,568
Accrued liabilities and deferred income1,3201,320
Total7,0853,888